UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person * Touchon Pascal				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/27/2022							X Officer (give title below) Other (specify below) President and CEO							
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)				(Instr. 8)		(A) or Dispose		Disposed	of (D)	Beneficia Reported	unt of Securities cially Owned Following ad Transaction(s)		Ownership Form:		7. Nature of Indirect Beneficial Ownership
				(Month/Day/Year			ode	V	Amou	(A) or (D)	Price	(Instr. 3 a	iu + <i>)</i>		or Ind (I) (Instr.	irect (I	(Instr. 4)	
Common Stock 06/27/2022			06/27/2022			S	(1)		14,22	0 D	\$ 7.2	472,093	472,093		D			
			Table II - I					quire	conta the fo d, Dis	ined i orm dis sposed	n this fo splays a of, or Bei	rm ar curre	e not requently valid	ction of in uired to re d OMB con	spond unle	ess	SEC 14	74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date	4. Transaction Code (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. 7 Am Un Sec	Fitle and nount of derlying curities str. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y De See Din or (I)	vnership rm of rivative curity: rect (D) Indirect	Ownersh (Instr. 4) D)		
						V	(A)		Date Exerc	cisable	Expiration Date	on Tit	Amount or Number of Shares					
Renor	ting ()	wners																

		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Touchon Pascal C/O ATARA BIOTHERAPEUTICS, INC 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		President and CEO					

Signatures

/s/ David Tucker, Attorney-in-Fact for Pascal Touchon	06/29/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.